StockNews.AI
EVOK
StockNews.AI
166 days

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

1. Evoke Pharma will release Q4 2024 earnings on March 13, 2025. 2. A conference call will discuss financial results at 4:30 p.m. ET. 3. Gimoti is the only FDA-approved treatment for diabetic gastroparesis. 4. Evoke's future growth is linked to GIMOTI prescription trends. 5. Forward-looking statements caution about potential operational risks.

Earnings
-3.28%Current Return
VS
-1.37%S&P 500
$3.9603/06 08:35 AM EDTEvent Start
$3.830203/07 03:00 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Neutral?

While upcoming earnings could indicate future trends, they present operational risks that might temper investor optimism. Historical precedents show earnings expectations often lead to volatility, but results will be key.

How important is it?

Upcoming earnings are crucial for gauging commercial success, particularly for GIMOTI. The company's dependency on this product heightens the stakes for its financial outlook.

Why Short Term?

The upcoming earnings report could shift sentiment quickly. Market reactions post-earnings often reflect immediate impressions of growth potential.

Related Companies

APRIEVOKASPN
SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 267-6316 and (203) 518-9783 for international callers. The conference ID number is EVOKQ424. The webcast details can be found in the events section of Evoke’s investor relations page. In addition, a replay of the call will be available until March 20, 2025. The replay dial-in numbers are (800) 723-0544 for domestic callers and (402) 220-2656 for international callers. About Evoke Pharma, Inc.Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information. Follow Evoke Pharma on LinkedInFollow Evoke Pharma on Twitter Safe Harbor StatementEvoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, the potential market opportunity for GIMOTI, Evoke’s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor & Media Contact:Daniel Kontoh-Boateng DKB PartnersTel: 862-213-1398dboateng@dkbpartners.net

Related News